Hoth Therapeutics, Inc.

NasdaqCM:HOTH Stock Report

Market Cap: US$5.4m

Hoth Therapeutics Management

Management criteria checks 3/4

Hoth Therapeutics' CEO is Robb Knie, appointed in May 2017, has a tenure of 7.58 years. total yearly compensation is $868.82K, comprised of 51.8% salary and 48.2% bonuses, including company stock and options. directly owns 0.84% of the company’s shares, worth $45.75K. The average tenure of the management team and the board of directors is 5.8 years and 4.8 years respectively.

Key information

Robb Knie

Chief executive officer

US$868.8k

Total compensation

CEO salary percentage51.8%
CEO tenure7.6yrs
CEO ownership0.8%
Management average tenure5.8yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury

Sep 20

Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule

Jun 29

Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation

Nov 12
Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation

Hoth Therapeutics extends agreement for experimental antibiotic

Jun 18

We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate

Jun 10
We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate

Hoth Therapeutics expands research agreement with VCU for COVID-19 therapeutic

May 05

Hoth Therapeutics shares rise 10% on developmental plans for HT-KIT in multiple orphan diseases and rare cancers

May 03

Hoth provides pipeline and regulatory timeline update

Feb 02

FDA grants Hoth Therapeutics Pre-IND meeting for HT-001, shares up 15%

Jan 13

Hoth Therapeutics to initiate IND enabling studies of HT-001 in cancer

Jan 11

Hoth Therapeutics inks deal for treatment of multi-drug resistant bacterial lung infections, shares up 15%

Jan 04

CEO Compensation Analysis

How has Robb Knie's remuneration changed compared to Hoth Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$8m

Jun 30 2024n/an/a

-US$7m

Mar 31 2024n/an/a

-US$8m

Dec 31 2023US$869kUS$450k

-US$8m

Sep 30 2023n/an/a

-US$10m

Jun 30 2023n/an/a

-US$10m

Mar 31 2023n/an/a

-US$11m

Dec 31 2022US$1mUS$450k

-US$11m

Sep 30 2022n/an/a

-US$11m

Jun 30 2022n/an/a

-US$12m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$1mUS$400k

-US$14m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$10m

Mar 31 2021n/an/a

-US$10m

Dec 31 2020US$781kUS$350k

-US$7m

Sep 30 2020n/an/a

-US$10m

Jun 30 2020n/an/a

-US$10m

Mar 31 2020n/an/a

-US$9m

Dec 31 2019US$2mUS$350k

-US$8m

Sep 30 2019n/an/a

-US$4m

Jun 30 2019n/an/a

-US$3m

Mar 31 2019n/an/a

-US$3m

Dec 31 2018US$308kUS$250k

-US$2m

Sep 30 2018n/an/a

-US$3m

Dec 31 2017US$146kUS$146k

-US$3m

Compensation vs Market: Robb's total compensation ($USD868.82K) is above average for companies of similar size in the US market ($USD650.00K).

Compensation vs Earnings: Robb's compensation has been consistent with company performance over the past year.

CEO

Robb Knie (55 yo)

7.6yrs

Tenure

US$868,823

Compensation

Mr. Robb Knie is Founder of Hoth Therapeutics, Inc. Mr. Knie served as the Chief Executive Officer, Chief Financial Officer and Chairman of the Board of Directors of FoxWayne Enterprises Acquisition Corp....

Leadership Team

NamePositionTenureCompensationOwnership
Robb Knie
Founder7.6yrsUS$868.82k0.84%
$ 45.7k
David Briones
Chief Financial Officer5.8yrsno datano data
Hayley Springer
Executive Vice President of Operations2.6yrsno datano data

5.8yrs

Average Tenure

Experienced Management: HOTH's management team is seasoned and experienced (5.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Robb Knie
Founder7.6yrsUS$868.82k0.84%
$ 45.7k
Adam Friedman
Member of Scientific Advisory Board7.4yrsno datano data
Mario Lacouture
Member of Scientific Advisory Board3.9yrsno datano data
David Sarnoff
Independent Director6.3yrsUS$65.21k0.014%
$ 786.7
William Weglicki
Member of Scientific Advisory Board5yrsno datano data
Wayne Linsley
Independent Director4.7yrsUS$65.21k0.0019%
$ 105.4
Glenn Cruse
Member of Scientific Advisory Board4.8yrsno datano data
Graig Springer
Independent Director4.8yrsUS$65.21k0.018%
$ 981.3
Sergio Traversa
Member of Scientific Advisory Boardno datano datano data
Jeff Pavell
Independent Director2yrsUS$65.21k0.074%
$ 4.0k
John Cirrito
Member of Scientific Advisory Board2.9yrsno datano data
Carla Yuede
Member of Scientific Advisory Board2.9yrsno datano data

4.8yrs

Average Tenure

56yo

Average Age

Experienced Board: HOTH's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 06:16
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hoth Therapeutics, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Jason KolbertD. Boral Capital LLC.
Raghuram SelvarajuH.C. Wainwright & Co.